SCHEMBL6319015

SCHEMBL6319015

CNC[C@@H](Cc1cccs1)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.45
CTSS P25774 1/20 0.45
CYP2C19 P33261 1/20 0.40
CTSC P53634 2/20 0.40
RAB9A P51151 3/20 0.40
RIPK1 Q13546 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
OPRM1 P35372 1/20 0.37
ADAM17 P78536 3/20 0.36
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
GBA1 P04062 1/20 0.35
BMP1 P13497 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318786 0.86 CTSK (0.45) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL8906214 0.82 CYP2C19 (0.50) CYP2C19CTSCRAB9ACYP3A4CYP2D6
SCHEMBL6317809 0.81 CTSK (0.47) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL6316639 0.81 CTSK (0.41) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL1401241 0.79 CYP2C19 (0.50) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL3266943 0.78 CTSK (0.47) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL3266809 0.76 CTSK (0.43) CTSKCTSSCYP2C19CTSCRAB9A
SCHEMBL22035319 0.76 GAA (0.40) CYP2C19CYP3A4CYP2D6LMNA
SCHEMBL21107811 0.73 AAK1 (0.32) CTSKCTSS
SCHEMBL6121860 0.72 RIPK1 (0.61) RAB9ARIPK1CYP3A4CYP2D6NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
US-5977178-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1999-11-02 US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 CTSK 1324/4885CTSS 2319/4885CYP2C19 3634/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR CTSK 1778/4885CTSS 2636/4885CYP2C19 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.